Clinical trial
International Concerted Action to Allocate Children, Adolescents and Young Adults With Relapsed and Refractory Leukemia/Lymphoma to the Right Therapy.
NCT05270096 is registered in ClinicalTrials.gov with Princess Maxima Center for Pediatric Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- International Concerted Action to Allocate Children, Adolescents and Young Adults With Relapsed and Refractory Leukemia/Lymphoma to the Right Therapy.
- Lead sponsor
- Princess Maxima Center for Pediatric Oncology
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- December 31, 2022
- Completion date
- June 1, 2032
- Enrollment
- 600 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
refractory hematologic malignancy, relapsed hematologic malignancy